QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
ASCO 2026 | Nordic oncology RWD at population scale
Oskar Ström and Johan Liseth Hansen will be attending the ASCO 2026 Annual Meeting in Chicago from 29 May to 2 June.
They will be meeting partners and discussing the Quantify Research Nordic Oncology RWD Platform — a study-ready data asset built specifically for oncology real-world evidence generation.
Why this matters for oncology research:
🔹 Built around the patient journey
Pre-defined cohorts cover major solid tumours and haematological malignancies, enabling treatment sequencing, outcomes […]
It’s a wrap for ISPOR 2026
After several days of insightful discussions, reconnecting with colleagues, and exchanging perspectives on the future of HEOR and RWE, we are now heading home from ISPOR 2026.
It has been a highly productive meeting for both Kelsi Smith, Puneet Kaushik and Abraham Choong, and also for our colleagues across the athagoras Group.
A special thank you to […]
Day 2 at ISPOR 2026: RWE is no longer a side discussion
A strong theme ran through Day 2:
Stakeholders have stopped debating whether real world evidence belongs at the decision table. The conversation has moved to how to generate RWE that is credible, transparent, and ready to inform real decisions.
Across sessions on rare oncology, IRA negotiations, value assessment, and publication standards, several priorities kept resurfacing:
🔹 methodological rigour and pre specification
🔹 transparency and reproducibility
🔹 earlier evidence planning across the product lifecycle
🔹 decision […]
What a way to end Day 1 at ISPOR 2026!🎷✨
From a packed calendar of back-to-back meetings and new connections to wrapping up the night with a Dixieland band and great food with the athagoras Group team, it’s been a fantastic start.
Missing a few connections today, but looking forward to catching up tomorrow. Getting rested and refreshed, and getting ready for Day 2!
[…]
